In addition, preclinical studies reveal that inhibition of NF-κB signaling cascade may sensitize various cancer cells including oral squamous cell carcinoma, HCC, colorectal cancer, and breast cancer to radiotherapy [11–14]. Here, NFKB1 is linked to cancer.